NASDAQ:PTGX Protagonist Therapeutics (PTGX) Stock Price, News & Analysis $131.62 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$131.71 +0.09 (+0.07%) As of 07/2/2026 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Protagonist Therapeutics Stock (NASDAQ:PTGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PTGX alerts:Sign Up Key Stats Today's Range$125.24▼$131.8750-Day Range$93.19▼$131.6252-Week Range$49.38▼$131.87Volume708,388 shsAverage Volume787,394 shsMarket Capitalization$8.46 billionP/E RatioN/ADividend YieldN/APrice Target$115.21Consensus RatingModerate Buy Company Overview Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care. Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease. PTG-200, a selective interleukin-23 receptor antagonist, is in Phase 2 clinical trials for moderate to severe Crohn’s disease. The company’s PTG-300 program is a hepcidin mimetic being evaluated in hematologic disorders characterized by iron overload, including polycythemia vera and myelofibrosis. Founded in 2006 and headquartered in San Diego, California, Protagonist Therapeutics conducts global clinical trials across North America, Europe and Asia. The company is led by a team of seasoned biotechnology executives with deep expertise in peptide drug discovery and development. Protagonist maintains collaborations with academic institutions and industry partners to advance its pipeline and explore additional therapeutic areas where oral peptide therapeutics may deliver significant patient benefit.AI Generated. May Contain Errors. Read More Protagonist Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScorePTGX MarketRank™: Protagonist Therapeutics scored higher than 22% of companies evaluated by MarketBeat, and ranked 746th out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingProtagonist Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 13 buy ratings, 1 hold rating, and 1 sell rating.Downside RiskProtagonist Therapeutics has a consensus price target of $115.21, representing about 12.5% downside from its current price of $131.62.Amount of Analyst CoverageProtagonist Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Protagonist Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.93 to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protagonist Therapeutics is -72.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Protagonist Therapeutics is -72.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProtagonist Therapeutics has a P/B Ratio of 13.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Protagonist Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.68% of the float of Protagonist Therapeutics has been sold short.Short Interest Ratio / Days to CoverProtagonist Therapeutics has a short interest ratio ("days to cover") of 11.59, which indicates bearish sentiment.Change versus previous monthShort interest in Protagonist Therapeutics has recently increased by 4.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProtagonist Therapeutics does not currently pay a dividend.Dividend GrowthProtagonist Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment0.83 News SentimentProtagonist Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Protagonist Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for PTGX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,539,792.00 in company stock.Percentage Held by Insiders5.19% of the stock of Protagonist Therapeutics is held by insiders.Percentage Held by Institutions98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Protagonist Therapeutics' insider trading history. Receive PTGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTGX Stock News HeadlinesWhy Wall Street’s wrong for loving Protagonist Therapeutics stockJuly 2, 2026 | msn.comWilliam Waddill Sells 9,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) StockJune 27, 2026 | americanbankingnews.com4th of July Chaikin flash saleMarc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his first-ever 4th of July flash sale through July 6th only. His Power Gauge Report membership comes with a free year of access to his Power Gauge Rating system, a 100% money-back guarantee, and a Hotlist of buy and sell ideas - including a little-known Nvidia partner he calls 'an upgrade to Tesla stock' in the autonomous vehicle race. His tools are used on Bloomberg and Reuters terminals worldwide and have helped investors grow assets by as much as 69,000%. | Chaikin Analytics (Ad)Protagonist Therapeutics (NASDAQ:PTGX) Cut to "Buy" at Wall Street ZenJune 27, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 SharesJune 26, 2026 | insidertrades.comProtagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On GoalJune 13, 2026 | seekingalpha.comGoldman Sachs Remains a Hold on Protagonist Therapeutics (PTGX)June 13, 2026 | theglobeandmail.comProtagonist Therapeutics (NASDAQ:PTGX) Director Sells $969,120.00 in StockJune 12, 2026 | insidertrades.comSee More Headlines PTGX Stock Analysis - Frequently Asked Questions How have PTGX shares performed this year? Protagonist Therapeutics' stock was trading at $87.34 on January 1st, 2026. Since then, PTGX stock has increased by 50.7% and is now trading at $131.62. How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its quarterly earnings results on Tuesday, May, 5th. The company reported $0.05 EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.55. The firm earned $56.37 million during the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative trailing twelve-month return on equity of 17.76%. When did Protagonist Therapeutics IPO? Protagonist Therapeutics (PTGX) raised $90 million in an initial public offering (IPO) on Wednesday, August 10th 2016. The company issued 7,500,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. How do I buy shares of Protagonist Therapeutics? Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY). Company Calendar Last Earnings5/05/2026Today7/05/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PTGX's financial health is in the Green zone, according to TradeSmith. PTGX has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTGX CIK1377121 Webwww.protagonist-inc.com Phone(510) 474-0170FaxN/AEmployees120Year Founded2006Price Target and Rating Average Price Target for Protagonist Therapeutics$115.21 High Price Target$137.00 Low Price Target$82.00 Potential Upside/Downside-12.5%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.81) Trailing P/E RatioN/A Forward P/E Ratio44.92 P/E GrowthN/ANet Income-$130.15 million Net Margins-154.88% Pretax Margin-155.78% Return on Equity-17.76% Return on Assets-16.47% Debt Debt-to-Equity RatioN/A Current Ratio17.76 Quick Ratio17.76 Sales & Book Value Annual Sales$46.02 million Price / Sales183.93 Cash FlowN/A Price / Cash FlowN/A Book Value$9.83 per share Price / Book13.39Miscellaneous Outstanding Shares64,310,000Free Float60,973,000Market Cap$8.46 billion OptionableOptionable Beta1.79 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:PTGX) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...Chaikin Analytics | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron, Unocal, and Texaco each confirmed the same energy technology worked - no fuel costs, no carb...Behind the Markets | Sponsored**MARKET CRASH WARNING**A former advisor to the Pentagon and CIA is warning that an 80% Dow drop could arrive within days - and names ...Paradigm Press | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
